Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
12:45pm, Friday, 03'rd Oct 2025
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are adv
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced one late-breaker oral platform presentation and two poster presentations to be presented at the International Con
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
11:51am, Thursday, 25'th Sep 2025
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short
10:05am, Wednesday, 24'th Sep 2025
Acadia Pharmaceuticals Inc. ACAD released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperph
Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges
09:32am, Wednesday, 24'th Sep 2025
Shares of Acadia Pharmaceuticals toppled Wednesday after the biotech company's experimental treatment for a rare, genetic disorder failed.
Acadia Pharmaceuticals' rare disease therapy fails late-stage trial
07:12am, Wednesday, 24'th Sep 2025
Acadia Pharmaceuticals said on Wednesday that its experimental therapy to treat a rare metabolic condition failed to meet the main goal in a late-stage study.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Developmental Medicine and Child Neurology published interim results from the caregiver-reported
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 08'th Sep 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 4, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) grante
ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
04:04pm, Monday, 08'th Sep 2025
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:45 AM EDT Company Participants Catherine Owen Adams - CEO & Director Mark Schney
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
04:05pm, Tuesday, 26'th Aug 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Morgan Stanley 23rd Annual Global Healthcare Con
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
04:05pm, Monday, 25'th Aug 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Konstantina (“Tina”) Katcheves as Senior Vice President, Chief Business and Strategy Offic
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 11'th Aug 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on August 5, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted i
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
11:05am, Thursday, 07'th Aug 2025
ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript
03:57am, Thursday, 07'th Aug 2025
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Al Kildani - Corporate Participant Catherine E. Owen Adams - CEO & Director E
